Immunological Considerations for COVID-19 Vaccine Strategies

Overview

Journal Nat Rev Immunol

Specialty Allergy & Immunology

Date 2020 Sep 5

PMID 32887954

Citations 509

Authors

Mangalakumari Jeyanathan

Sam Afkhami

Fiona Smaill

Matthew S Miller

Brian D Lichty

Zhou Xing

Affiliations

Soon will be listed here.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the most formidable challenge to humanity in a century. It is widely believed that prepandemic normalcy will never return until a safe and effective vaccine strategy becomes available and a global vaccination programme is implemented successfully. Here, we discuss the immunological principles that need to be taken into consideration in the development of COVID-19 vaccine strategies. On the basis of these principles, we examine the current COVID-19 vaccine candidates, their strengths and potential shortfalls, and make inferences about their chances of success. Finally, we discuss the scientific and practical challenges that will be faced in the process of developing a successful vaccine and the ways in which COVID-19 vaccine strategies may evolve over the next few years.

Citing Articles

Cellular immune breadth of an Omicron-specific, self-amplifying monovalent mRNA vaccine booster for COVID-19.

Kumar D, Gaikwad K, Gunnale R, Vishwakarma S, Shukla S, Srivastava S NPJ Vaccines. 2025; 10(1):42.

PMID: 40025095 PMC: 11873296. DOI: 10.1038/s41541-025-01076-2.

A novel platform for engineered AAV-based vaccines.

Babutzka S, Gehrke M, Papadopoulou A, Diedrichs-Mohring M, Giannaki M, Hennis L Mol Ther Methods Clin Dev. 2025; 33(1):101418.

PMID: 40008090 PMC: 11850754. DOI: 10.1016/j.omtm.2025.101418.

CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.

Dandotiya J, Adhikari N, Tripathy M, Jakhar K, Sonar S, Pati D Front Immunol. 2025; 15:1447962.

PMID: 39911577 PMC: 11794485. DOI: 10.3389/fimmu.2024.1447962.

SARS-CoV-2 Evolution: Implications for Diagnosis, Treatment, Vaccine Effectiveness and Development.

Angius F, Puxeddu S, Zaimi S, Canton S, Nematollahzadeh S, Pibiri A Vaccines (Basel). 2025; 13(1).

PMID: 39852796 PMC: 11769326. DOI: 10.3390/vaccines13010017.

Safety, efficacy, and immunogenicity of SARS-CoV-2 mRNA vaccination in children and adult patients with rheumatic diseases: a comprehensive literature review.

Dhanasekaran P, Karasu B, Mak A Rheumatol Int. 2024; 44(12):2757-2794.

PMID: 39576327 DOI: 10.1007/s00296-024-05734-x.

References

Wu L, Wang N, Chang Y, Tian X, Na D, Zhang L . Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2008; 13(10):1562-4. PMC: 2851497. DOI: 10.3201/eid1310.070576. View

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y . Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020; 71(16):2027-2034. PMC: 7184337. DOI: 10.1093/cid/ciaa344. View

Zhao J, Zhao J, Perlman S . T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol. 2010; 84(18):9318-25. PMC: 2937604. DOI: 10.1128/JVI.01049-10. View

Lurie N, Saville M, Hatchett R, Halton J . Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020; 382(21):1969-1973. DOI: 10.1056/NEJMp2005630. View

Folegatti P, Bittaye M, Flaxman A, Lopez F, Bellamy D, Kupke A . Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis. 2020; 20(7):816-826. PMC: 7172901. DOI: 10.1016/S1473-3099(20)30160-2. View

Netland J, DeDiego M, Zhao J, Fett C, Alvarez E, Nieto-Torres J . Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease. Virology. 2010; 399(1):120-128. PMC: 2830353. DOI: 10.1016/j.virol.2010.01.004. View

Yu H, Sun B, Fang Z, Zhao J, Liu X, Li Y . Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. Eur Respir J. 2020; 56(2). PMC: 7236821. DOI: 10.1183/13993003.01526-2020. View

Draper S, Heeney J . Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol. 2009; 8(1):62-73. DOI: 10.1038/nrmicro2240. View

Bollyky T, Gostin L, Hamburg M . The Equitable Distribution of COVID-19 Therapeutics and Vaccines. JAMA. 2020; 323(24):2462-2463. DOI: 10.1001/jama.2020.6641. View

10.

Puelles V, Lutgehetmann M, Lindenmeyer M, Sperhake J, Wong M, Allweiss L . Multiorgan and Renal Tropism of SARS-CoV-2. N Engl J Med. 2020; 383(6):590-592. PMC: 7240771. DOI: 10.1056/NEJMc2011400. View

11.

Duan J, Yan X, Guo X, Cao W, Han W, Qi C . A human SARS-CoV neutralizing antibody against epitope on S2 protein. Biochem Biophys Res Commun. 2005; 333(1):186-93. PMC: 7092839. DOI: 10.1016/j.bbrc.2005.05.089. View

12.

Sanche S, Lin Y, Xu C, Romero-Severson E, Hengartner N, Ke R . High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis. 2020; 26(7):1470-1477. PMC: 7323562. DOI: 10.3201/eid2607.200282. View

13.

Burton D, Walker L . Rational Vaccine Design in the Time of COVID-19. Cell Host Microbe. 2020; 27(5):695-698. PMC: 7219357. DOI: 10.1016/j.chom.2020.04.022. View

14.

Netea M, Giamarellos-Bourboulis E, Dominguez-Andres J, Curtis N, van Crevel R, van de Veerdonk F . Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection. Cell. 2020; 181(5):969-977. PMC: 7196902. DOI: 10.1016/j.cell.2020.04.042. View

15.

Jimenez-Guardeno J, Regla-Nava J, Nieto-Torres J, DeDiego M, Castano-Rodriguez C, Fernandez-Delgado R . Identification of the Mechanisms Causing Reversion to Virulence in an Attenuated SARS-CoV for the Design of a Genetically Stable Vaccine. PLoS Pathog. 2015; 11(10):e1005215. PMC: 4626112. DOI: 10.1371/journal.ppat.1005215. View

16.

van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham J, Port J . ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020; 586(7830):578-582. PMC: 8436420. DOI: 10.1038/s41586-020-2608-y. View

17.

Del Giudice G, Rappuoli R, Didierlaurent A . Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin Immunol. 2018; 39:14-21. DOI: 10.1016/j.smim.2018.05.001. View

18.

HogenEsch H, OHagan D, Fox C . Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ Vaccines. 2018; 3:51. PMC: 6180056. DOI: 10.1038/s41541-018-0089-x. View

19.

Yao Y, Jeyanathan M, Haddadi S, Barra N, Vaseghi-Shanjani M, Damjanovic D . Induction of Autonomous Memory Alveolar Macrophages Requires T Cell Help and Is Critical to Trained Immunity. Cell. 2018; 175(6):1634-1650.e17. DOI: 10.1016/j.cell.2018.09.042. View

20.

Arunachalam P, Charles T, Joag V, Bollimpelli V, Scott M, Wimmers F . T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. Nat Med. 2020; 26(6):932-940. PMC: 7303014. DOI: 10.1038/s41591-020-0858-8. View